Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SIGLEC27P is a human pseudogene that is annotated as "Sialic acid binding Ig-like lectin 27, pseudogene." It belongs to a family of sialic acid-recognizing immunoglobulin-like lectins (Siglecs), but does not produce a functional protein due to disruptive mutations in the gene sequence[3][1][7]. The "pseudogene" classification indicates it is evolutionarily related to gene-encoded receptors with potential immune regulatory functions but is not itself expressed as a protein or associated with known biological activities or disease mechanisms[4][5][6]. Synonyms include SIGLECP11[1][3][7]. There is no evidence of molecular function, therapeutic relevance, biomarker status, or drug interactors for SIGLEC27P. Summary: SIGLEC27P is a pseudogene and not a functional protein target; it is unsuitable for therapeutic targeting, disease association studies, or biomarker development[3][1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Sialic acid binding Ig-like lectin 27, pseudogene (SIGLEC27P).